[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital mortality, length of stay total charges, and stroke morbidity among inpatient admissions with a principal diagnosis of ischemic stroke.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of Stroke.\nIschemic Stroke + Atrial Fibrillation Categories:\n\nIschemic Stroke with Atrial Fibrillation\nIschemic Stroke without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nStroke-related morbidity\n\nIntracranial Hemorrhage\nSepsis\n\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, rheumatic valvular disease, chronic obstructive pulmonary disease, dementia, cirrhosis, obstructive sleep apnea, anemia, obesity, prior stroke, prior cardiac surgery, presence of pacemaker/defibrillator, alochol use disorder, tobacco use disorder, use of tissue plasminogen activator and use of thrombectomy.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital mortality, length of stay total charges, and stroke morbidity among inpatient admissions with a principal diagnosis of ischemic stroke.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of Stroke.\nIschemic Stroke + Atrial Fibrillation Categories:\n\nIschemic Stroke with Atrial Fibrillation\nIschemic Stroke without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nStroke-related morbidity\n\nIntracranial Hemorrhage\nSepsis\n\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, rheumatic valvular disease, chronic obstructive pulmonary disease, dementia, cirrhosis, obstructive sleep apnea, anemia, obesity, prior stroke, prior cardiac surgery, presence of pacemaker/defibrillator, alochol use disorder, tobacco use disorder, use of tissue plasminogen activator and use of thrombectomy.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 9,280\n1\nIschemic Stroke with Atrial Fibrillation\nN = 1,975\n1\nIschemic Stroke without Atrial Fibrillation\nN = 7,305\n1\np-value\n2\n\n\n\n\nAge, y\n70 (14)\n77 (11)\n68 (14)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n0.53\n\n\n    Female\n4,545 (49)\n995 (50)\n3,550 (49)\n\n\n\n\n    Male\n4,735 (51)\n980 (50)\n3,755 (51)\n\n\n\n\nRace\n\n\n\n\n\n\n0.003\n\n\n    White\n5,780 (63)\n1,365 (70)\n4,415 (61)\n\n\n\n\n    Asian or Pacific Islander\n355 (3.9)\n85 (4.4)\n270 (3.8)\n\n\n\n\n    Black\n1,585 (17)\n250 (13)\n1,335 (19)\n\n\n\n\n    Hispanic\n1,085 (12)\n150 (7.7)\n935 (13)\n\n\n\n\n    Native American\n40 (0.4)\n10 (0.5)\n30 (0.4)\n\n\n\n\n    Other\n280 (3.1)\n80 (4.1)\n200 (2.8)\n\n\n\n\nCharlson comorbidity index\n3.92 (2.15)\n4.28 (2.35)\n3.82 (2.08)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n0.006\n\n\n    $1 - $51,999\n2,875 (32)\n525 (27)\n2,350 (33)\n\n\n\n\n    $52,000 - $65,999\n2,435 (27)\n495 (26)\n1,940 (27)\n\n\n\n\n    $66,000 - $87,999\n2,080 (23)\n455 (23)\n1,625 (23)\n\n\n\n\n    $88,000 or more\n1,655 (18)\n465 (24)\n1,190 (17)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n2,375 (26)\n300 (15)\n2,075 (28)\n\n\n\n\n    Medicaid\n865 (9.3)\n65 (3.3)\n800 (11)\n\n\n\n\n    Medicare\n5,760 (62)\n1,560 (79)\n4,200 (58)\n\n\n\n\n    Other\n265 (2.9)\n50 (2.5)\n215 (2.9)\n\n\n\n\nHospital region\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n885 (9.5)\n175 (8.9)\n710 (9.7)\n\n\n\n\n    Northeast\n1,120 (12)\n335 (17)\n785 (11)\n\n\n\n\n    South\n4,785 (52)\n875 (44)\n3,910 (54)\n\n\n\n\n    West\n2,490 (27)\n590 (30)\n1,900 (26)\n\n\n\n\nHospital bedsize\n\n\n\n\n\n\n0.94\n\n\n    Large\n5,140 (55)\n1,105 (56)\n4,035 (55)\n\n\n\n\n    Medium\n2,820 (30)\n585 (30)\n2,235 (31)\n\n\n\n\n    Small\n1,320 (14)\n285 (14)\n1,035 (14)\n\n\n\n\nHospital location and teaching status\n\n\n\n\n\n\n0.052\n\n\n    Rural\n505 (5.4)\n105 (5.3)\n400 (5.5)\n\n\n\n\n    Urban, non-teaching\n1,835 (20)\n305 (15)\n1,530 (21)\n\n\n\n\n    Urban, teaching\n6,940 (75)\n1,565 (79)\n5,375 (74)\n\n\n\n\nHypertension\n7,930 (85)\n1,760 (89)\n6,170 (84)\n0.019\n\n\nDiabetes mellitus\n4,000 (43)\n785 (40)\n3,215 (44)\n0.14\n\n\nHyperlipidemia\n5,705 (61)\n1,150 (58)\n4,555 (62)\n0.14\n\n\nCoronary artery disease\n2,295 (25)\n620 (31)\n1,675 (23)\n0.001\n\n\nPeripheral vascular disease\n790 (8.5)\n225 (11)\n565 (7.7)\n0.024\n\n\nHeart failure\n1,805 (19)\n680 (34)\n1,125 (15)\n&lt;0.001\n\n\nChronic kidney disease\n1,730 (19)\n465 (24)\n1,265 (17)\n0.005\n\n\nRheumatic valvular disease\n260 (2.8)\n75 (3.8)\n185 (2.5)\n0.18\n\n\nChronic obstructive pulmonary disease\n1,450 (16)\n365 (18)\n1,085 (15)\n0.074\n\n\nDementia\n1,030 (11)\n325 (16)\n705 (9.7)\n&lt;0.001\n\n\nCirrhosis\n90 (1.0)\n10 (0.5)\n80 (1.1)\n0.29\n\n\nObstructive sleep apnea\n630 (6.8)\n155 (7.8)\n475 (6.5)\n0.32\n\n\nAnemia\n320 (3.4)\n95 (4.8)\n225 (3.1)\n0.10\n\n\nObesity\n1,530 (16)\n280 (14)\n1,250 (17)\n0.15\n\n\nPrior stroke\n1,485 (16)\n375 (19)\n1,110 (15)\n0.077\n\n\nPrior cardiac surgery\n655 (7.1)\n215 (11)\n440 (6.0)\n0.001\n\n\nPacemaker/ICD\n450 (4.8)\n240 (12)\n210 (2.9)\n&lt;0.001\n\n\nAlcohol use disorder\n3,595 (39)\n840 (43)\n2,755 (38)\n0.087\n\n\nTobbacco use disorder\n80 (0.9)\n5 (0.3)\n75 (1.0)\n0.14\n\n\nTissue plasminogen activator\n845 (9.1)\n195 (9.9)\n650 (8.9)\n0.54\n\n\nThrombectomy use\n385 (4.1)\n120 (6.1)\n265 (3.6)\n0.039\n\n\n\n1\nMean (SD); n (%)\n\n\n2\nDesign-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 9,280\n1\nIschemic Stroke with Atrial Fibrillation\nN = 1,975\n1\nIschemic Stroke without Atrial Fibrillation\nN = 7,305\n1\np-value\n2\n\n\n\n\nDied during hospitalization\n335 (3.6)\n90 (4.6)\n245 (3.4)\n0.25\n\n\nLength of stay (days)\n5.4 (6.9)\n6.0 (6.1)\n5.2 (7.1)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n78,028 (98,927)\n86,453 (102,066)\n75,750 (97,973)\n0.014\n\n\nStroke-related morbidity\n630 (6.8)\n225 (11)\n405 (5.5)\n&lt;0.001\n\n\nIntracranial Hemorrhage\n545 (5.9)\n200 (10)\n345 (4.7)\n&lt;0.001\n\n\nSepsis\n105 (1.1)\n30 (1.5)\n75 (1.0)\n0.39\n\n\n\n1\nn (%); Mean (SD)\n\n\n2\nPearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n1.05 (0.53 to 2.10)\n0.88\n\n\nAge, y\n1.03 (1.00 to 1.05)\n0.052\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.26 (0.73 to 2.16)\n0.40\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n0.73 (0.10 to 5.48)\n0.76\n\n\n    Black\n0.58 (0.23 to 1.46)\n0.25\n\n\n    Hispanic\n1.32 (0.57 to 3.06)\n0.52\n\n\n    Native American\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\n    Other\n1.57 (0.34 to 7.20)\n0.56\n\n\nCharlson comorbidity index\n1.15 (0.98 to 1.35)\n0.079\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.97 (0.49 to 1.91)\n0.92\n\n\n    $66,000 - $87,999\n0.44 (0.17 to 1.13)\n0.087\n\n\n    $88,000 or more\n1.14 (0.56 to 2.32)\n0.73\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n0.71 (0.17 to 3.06)\n0.65\n\n\n    Medicare\n0.78 (0.40 to 1.50)\n0.46\n\n\n    Other\n1.95 (0.64 to 5.92)\n0.24\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.76 (0.27 to 2.16)\n0.61\n\n\n    South\n0.50 (0.21 to 1.19)\n0.12\n\n\n    West\n0.32 (0.12 to 0.90)\n0.031\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.68 (0.36 to 1.29)\n0.24\n\n\n    Small\n0.64 (0.24 to 1.65)\n0.35\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n0.51 (0.15 to 1.72)\n0.28\n\n\n    Urban, teaching\n0.78 (0.27 to 2.26)\n0.64\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.69 (0.32 to 1.47)\n0.34\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.44 to 1.79)\n0.74\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.46 (0.25 to 0.87)\n0.017\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.56 (0.27 to 1.14)\n0.11\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.67 (0.21 to 2.08)\n0.48\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.57 (1.25 to 5.27)\n0.010\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.00 (0.44 to 2.29)\n&gt;0.99\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.09 (0.51 to 2.31)\n0.82\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.34 (0.64 to 2.80)\n0.43\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.69 (1.01 to 21.9)\n0.049\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.53 (0.11 to 2.62)\n0.43\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.24 (0.28 to 5.41)\n0.78\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.46 to 1.46)\n0.50\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.84 (0.34 to 2.05)\n0.70\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.46 (0.06 to 3.70)\n0.47\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.18 (0.04 to 0.74)\n0.018\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.47 (0.52 to 4.10)\n0.46\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.48 (0.10 to 2.16)\n0.34\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n3.74 (1.57 to 8.89)\n0.003\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nStroke-Related Morbidity (ICH and Sepsis):\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.45 (0.28 to 0.72)\n0.001\n\n\nAge, y\n1.00 (0.98 to 1.02)\n0.92\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.44 (0.94 to 2.18)\n0.090\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.02 (0.34 to 3.05)\n0.98\n\n\n    Black\n0.66 (0.34 to 1.28)\n0.21\n\n\n    Hispanic\n1.08 (0.56 to 2.07)\n0.82\n\n\n    Native American\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\n    Other\n0.90 (0.17 to 4.83)\n0.90\n\n\nCharlson comorbidity index\n1.07 (0.95 to 1.21)\n0.25\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n1.05 (0.63 to 1.75)\n0.85\n\n\n    $66,000 - $87,999\n0.72 (0.40 to 1.30)\n0.28\n\n\n    $88,000 or more\n1.14 (0.61 to 2.15)\n0.68\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n1.06 (0.47 to 2.38)\n0.88\n\n\n    Medicare\n1.07 (0.58 to 1.97)\n0.82\n\n\n    Other\n0.82 (0.22 to 3.15)\n0.78\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.87 (0.38 to 1.98)\n0.74\n\n\n    South\n0.82 (0.40 to 1.68)\n0.59\n\n\n    West\n0.82 (0.36 to 1.87)\n0.64\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.71 (0.43 to 1.16)\n0.17\n\n\n    Small\n0.39 (0.17 to 0.93)\n0.033\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n5,307,637 (2,816,055 to 10,003,715)\n&lt;0.001\n\n\n    Urban, teaching\n7,170,497 (4,605,270 to 11,164,605)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.77 (0.44 to 1.37)\n0.37\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.95 (0.59 to 1.53)\n0.84\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.00 (0.62 to 1.61)\n&gt;0.99\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.02 (0.63 to 1.65)\n0.95\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.67 (0.33 to 1.39)\n0.28\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.63 (0.93 to 2.88)\n0.091\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.87 (0.48 to 1.58)\n0.64\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.94 (0.52 to 1.72)\n0.85\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.61 (0.29 to 1.31)\n0.21\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n3.90 (0.98 to 15.6)\n0.054\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.06 (1.07 to 3.94)\n0.030\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.83 (0.76 to 4.43)\n0.18\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.76 (0.48 to 1.21)\n0.24\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.69 (0.39 to 1.23)\n0.21\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.10 (0.33 to 3.72)\n0.88\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.77 (0.42 to 1.43)\n0.41\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.47 (0.14 to 1.53)\n0.21\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.02 (0.41 to 2.57)\n0.97\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.12 (0.17 to 7.23)\n0.91\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.79 (0.37 to 1.68)\n0.54\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n5.84 (3.18 to 10.7)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nIntracranial Hemorrhage:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.45 (0.27 to 0.77)\n0.003\n\n\nAge, y\n1.00 (0.98 to 1.02)\n0.85\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.22 (0.78 to 1.90)\n0.38\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n0.56 (0.11 to 2.76)\n0.47\n\n\n    Black\n0.60 (0.29 to 1.22)\n0.16\n\n\n    Hispanic\n0.95 (0.45 to 2.03)\n0.90\n\n\n    Native American\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\n    Other\n0.32 (0.04 to 2.73)\n0.30\n\n\nCharlson comorbidity index\n1.08 (0.95 to 1.22)\n0.24\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n1.27 (0.73 to 2.20)\n0.40\n\n\n    $66,000 - $87,999\n0.90 (0.48 to 1.67)\n0.73\n\n\n    $88,000 or more\n1.24 (0.64 to 2.40)\n0.53\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n0.51 (0.18 to 1.48)\n0.21\n\n\n    Medicare\n1.00 (0.53 to 1.89)\n&gt;0.99\n\n\n    Other\n0.53 (0.12 to 2.40)\n0.41\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.85 (0.36 to 2.02)\n0.71\n\n\n    South\n0.82 (0.39 to 1.74)\n0.61\n\n\n    West\n0.85 (0.36 to 2.00)\n0.70\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.59 (0.35 to 0.99)\n0.045\n\n\n    Small\n0.42 (0.18 to 1.00)\n0.049\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n3,855,513 (1,978,674 to 7,512,597)\n&lt;0.001\n\n\n    Urban, teaching\n6,080,202 (3,896,952 to 9,486,609)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.68 (0.38 to 1.23)\n0.20\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.94 (0.57 to 1.56)\n0.82\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.49 to 1.35)\n0.43\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.29 (0.77 to 2.15)\n0.33\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.84 (0.41 to 1.72)\n0.64\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.54 (0.83 to 2.83)\n0.17\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.83 (0.44 to 1.58)\n0.57\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.91 (0.50 to 1.68)\n0.77\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.52 (0.22 to 1.25)\n0.15\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.68 (1.11 to 19.6)\n0.035\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.67 (0.80 to 3.50)\n0.17\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.84 (0.73 to 4.67)\n0.20\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.71 (0.43 to 1.18)\n0.19\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.72 (0.40 to 1.31)\n0.29\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.78 (0.18 to 3.34)\n0.74\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.92 (0.48 to 1.80)\n0.82\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.46 (0.13 to 1.57)\n0.21\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.97 (0.37 to 2.54)\n0.95\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.48 (0.21 to 10.3)\n0.69\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.94 (0.44 to 2.04)\n0.89\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n6.29 (3.45 to 11.5)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nSepsis:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.36 (0.11 to 1.18)\n0.092\n\n\nAge, y\n1.01 (0.95 to 1.06)\n0.85\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n8.00 (1.44 to 44.3)\n0.017\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n7.11 (1.24 to 40.8)\n0.028\n\n\n    Black\n1.02 (0.20 to 5.13)\n0.98\n\n\n    Hispanic\n1.72 (0.36 to 8.22)\n0.49\n\n\n    Native American\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\n    Other\n16.0 (2.03 to 127)\n0.009\n\n\nCharlson comorbidity index\n1.02 (0.77 to 1.34)\n0.89\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.29 (0.06 to 1.42)\n0.13\n\n\n    $66,000 - $87,999\n0.11 (0.02 to 0.69)\n0.018\n\n\n    $88,000 or more\n1.13 (0.28 to 4.62)\n0.87\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n6.48 (0.77 to 54.4)\n0.085\n\n\n    Medicare\n1.27 (0.14 to 11.4)\n0.83\n\n\n    Other\n7.03 (1.16 to 42.5)\n0.034\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.52 (0.04 to 6.52)\n0.61\n\n\n    South\n0.37 (0.05 to 2.78)\n0.33\n\n\n    West\n0.31 (0.02 to 4.12)\n0.38\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n1.63 (0.54 to 4.89)\n0.38\n\n\n    Small\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n103,239,714 (21,759,123 to 489,837,702)\n&lt;0.001\n\n\n    Urban, teaching\n103,472,829 (23,283,378 to 459,839,911)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.61 (0.39 to 6.69)\n0.51\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.66 (0.18 to 2.46)\n0.53\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.63 (0.74 to 9.40)\n0.14\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n6.34 (1.88 to 21.4)\n0.003\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.17 to 4.12)\n0.81\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.03 (0.19 to 5.54)\n0.97\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.33 (0.32 to 5.55)\n0.69\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n26.0 (2.96 to 228)\n0.003\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.36 (1.33 to 14.3)\n0.015\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.17 (0.67 to 26.0)\n0.13\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.02 (0.34 to 3.03)\n0.97\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.57 (0.18 to 1.78)\n0.34\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.59 (0.51 to 13.1)\n0.25\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.12 (0.03 to 0.47)\n0.002\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.20 (0.13 to 36.9)\n0.58\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (0.00 to 0.00)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.29 (0.01 to 7.34)\n0.45\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n-0.65 (-1.4 to 0.10)\n0.088\n\n\nAge, y\n-0.02 (-0.05 to 0.01)\n0.20\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n0.35 (-0.21 to 0.91)\n0.22\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n0.49 (-1.1 to 2.0)\n0.54\n\n\n    Black\n0.92 (-0.01 to 1.9)\n0.053\n\n\n    Hispanic\n0.38 (-0.87 to 1.6)\n0.55\n\n\n    Native American\n-1.5 (-4.2 to 1.1)\n0.26\n\n\n    Other\n0.75 (-0.79 to 2.3)\n0.34\n\n\nCharlson comorbidity index\n0.24 (0.05 to 0.43)\n0.015\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.48 (-0.48 to 1.4)\n0.32\n\n\n    $66,000 - $87,999\n-0.09 (-0.86 to 0.68)\n0.83\n\n\n    $88,000 or more\n0.53 (-0.38 to 1.4)\n0.26\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n2.5 (0.47 to 4.5)\n0.016\n\n\n    Medicare\n0.33 (-0.57 to 1.2)\n0.47\n\n\n    Other\n1.2 (-0.46 to 2.9)\n0.16\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.89 (-0.56 to 2.3)\n0.23\n\n\n    South\n0.74 (-0.63 to 2.1)\n0.29\n\n\n    West\n0.11 (-1.3 to 1.6)\n0.88\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n-0.51 (-1.3 to 0.31)\n0.22\n\n\n    Small\n-1.5 (-2.4 to -0.65)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n-0.05 (-1.0 to 0.91)\n0.91\n\n\n    Urban, teaching\n1.4 (0.47 to 2.4)\n0.003\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.17 (-1.4 to 1.0)\n0.78\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.15 (-0.54 to 0.83)\n0.67\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.62 (-1.5 to 0.25)\n0.16\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.15 (-0.96 to 0.65)\n0.71\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.06 (-1.2 to 1.3)\n0.93\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.2 (0.74 to 3.7)\n0.003\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.00 (-1.1 to 1.1)\n&gt;0.99\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.01 (-0.71 to 0.69)\n0.98\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.48 (-0.36 to 1.3)\n0.26\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.6 (-2.9 to 8.2)\n0.35\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.12 (-0.89 to 1.1)\n0.81\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.0 (-0.44 to 2.5)\n0.17\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.58 (-1.4 to 0.20)\n0.14\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.91 (-1.6 to -0.24)\n0.007\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.29 (-1.8 to 2.3)\n0.78\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.46 (-1.3 to 0.41)\n0.30\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-1.2 (-2.3 to -0.06)\n0.038\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.61 (-1.9 to 0.72)\n0.37\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.46 (-2.8 to 1.9)\n0.70\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.22 (-1.0 to 0.60)\n0.59\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.3 (-0.17 to 2.7)\n0.083\n\n\n\n1\nCI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n-8,289 (-19,967 to 3,389)\n0.16\n\n\nAge, y\n-553 (-1,032 to -74)\n0.024\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n8,054 (-509 to 16,617)\n0.065\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n15,845 (-10,356 to 42,046)\n0.24\n\n\n    Black\n-1,049 (-12,650 to 10,552)\n0.86\n\n\n    Hispanic\n9,519 (-8,129 to 27,167)\n0.29\n\n\n    Native American\n-28,510 (-60,964 to 3,943)\n0.085\n\n\n    Other\n37,149 (-1,735 to 76,034)\n0.061\n\n\nCharlson comorbidity index\n2,718 (-916 to 6,351)\n0.14\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n2,806 (-10,718 to 16,330)\n0.68\n\n\n    $66,000 - $87,999\n1,077 (-11,691 to 13,845)\n0.87\n\n\n    $88,000 or more\n3,861 (-11,554 to 19,276)\n0.62\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n25,881 (5,675 to 46,087)\n0.012\n\n\n    Medicare\n9,518 (-1,161 to 20,197)\n0.081\n\n\n    Other\n1,374 (-20,153 to 22,902)\n0.90\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n24,654 (7,916 to 41,393)\n0.004\n\n\n    South\n22,857 (11,584 to 34,130)\n&lt;0.001\n\n\n    West\n40,078 (24,158 to 55,997)\n&lt;0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n-6,927 (-18,976 to 5,121)\n0.26\n\n\n    Small\n-22,612 (-33,541 to -11,683)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n19,595 (7,160 to 32,030)\n0.002\n\n\n    Urban, teaching\n34,430 (22,920 to 45,939)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-1,268 (-17,788 to 15,253)\n0.88\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2,081 (-6,978 to 11,140)\n0.65\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-11,093 (-21,413 to -774)\n0.035\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n3,074 (-8,888 to 15,035)\n0.61\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n151 (-15,676 to 15,978)\n0.99\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n22,938 (4,702 to 41,173)\n0.014\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1,828 (-11,386 to 15,041)\n0.79\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-5,550 (-16,873 to 5,773)\n0.34\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-4,541 (-16,988 to 7,906)\n0.47\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n83,037 (-102,849 to 268,923)\n0.38\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n5,681 (-13,995 to 25,356)\n0.57\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n20,933 (-2,909 to 44,776)\n0.085\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-751 (-12,100 to 10,598)\n0.90\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-9,052 (-18,275 to 171)\n0.054\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n12,176 (-11,238 to 35,590)\n0.31\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-8,430 (-16,606 to -255)\n0.043\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-20,961 (-38,052 to -3,870)\n0.016\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-15,117 (-34,551 to 4,318)\n0.13\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-1,326 (-31,032 to 28,381)\n0.93\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n39,082 (23,319 to 54,845)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n97,324 (70,383 to 124,265)\n&lt;0.001\n\n\n\n1\nCI = Confidence Interval"
  }
]